Curatis Holding AG (SWX: CURN)
Health Care · Pharmaceuticals · CH
CHF19.70
+12.57% today · +53.3% 1Y
Curatis Holding AG (SWX: CURN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $125.99M and employs 9 people.
Over the last twelve months the share price has gained 53.3%, trading between 11.05 and 27.90.
Tweenvest scores Curatis Holding AG across four factors: quality 77/100, value 69/100. Its strongest factor is quality.
CURN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $125.99M
- Revenue (TTM)
- $16.70M
- P/E
- —
- EPS
- -0.13
- Dividend yield
- —
- Beta (5Y)
- -0.71
- 52-week high
- CHF27.90
- 52-week low
- CHF11.05
- Avg volume (3M)
- —
- Shares outstanding
- 5.31M
- Employees
- 9
- Next earnings
- —
About Curatis Holding AG
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.
- ISIN
- CH1330780979
- Founded
- 2002
- Listed since
- Apr 16, 1999
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| MPH Health Care AGDB: 93M1 | $128.48M | €26.80 | +1.13% |
| Sunhawk Vision Biotech, Inc.TPEX: 7759 | $126.93M | NT$57.70 | +35.61% |
| JW Lifescience CorporationKOSE: A234080 | $126.01M | ₩10,940.00 | -0.82% |
| Jerusalem Pharmaceuticals Co. Ltd.PLSE: JPH | $126.00M | $3.50 | -0.85% |
| Kopran LimitedBSE: 524280 | $125.38M | Rs251.30 | -10.97% |
| Vikram Thermo (India) LimitedBSE: 530477 | $124.99M | Rs385.75 | -4.96% |
| Orient EuroPharma Co., Ltd.TPEX: 4120 | $124.80M | NT$46.00 | -0.22% |
| Semnur Pharmaceuticals, Inc.OTCPK: SMNR | $124.31M | $0.54 | +20.00% |
Figures last refreshed Oct 11, 2026.